Refine
Document Type
- Article (4)
Has Fulltext
- yes (4)
Is part of the Bibliography
- no (4)
Keywords
- ALK-rearranged NSCLC (1)
- Abatacept (1)
- Astronaut <Motiv> (1)
- Azathioprine (1)
- Bedeutungslosigkeit (1)
- Chemotherapy (1)
- Conventional synthetic disease-modifying antirheumatic drug (1)
- Einsamkeit <Motiv> (1)
- Hydroxychloroquine (1)
- Leflunomide (1)
- Lung Cancer (1)
- Mem (1)
- Methotrexate (1)
- Non-small cell lung cancer (1)
- Prognosis (1)
- ROS1 (1)
- Rheumatoid arthritis (1)
- Sulfasalazine (1)
- TP53 mutation status (1)
- Weltraum <Motiv> (1)
- sequential ALK-inhibitor therapy (1)
Institute
- Medizin (3)
Background: Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a wealth of data supporting the use of abatacept in combination with MTX, but data on alternative conventional synthetic disease-modifying antirheumatic drug (csDMARD) combinations with abatacept are scarce.
Methods: In this post-hoc exploratory analysis, efficacy and safety data were extracted from abatacept RA studies in which combination with csDMARDs other than MTX was permitted: three interventional trials (ATTAIN, ASSURE, and ARRIVE) and one real-world study (ACTION). Patients with moderate-to-severe RA received abatacept in combination with MTX, hydroxychloroquine, sulfasalazine, azathioprine, or leflunomide for 6 months to 2 years according to the study design. Change from baseline in physical function (Health Assessment Questionnaire—Disability Index (HAQ-DI); all studies) and 28-joint Disease Activity Score (C-reactive protein) (DAS28 (CRP); ATTAIN, ARRIVE, and ACTION), American College of Rheumatology response rates (ATTAIN), and safety were assessed for individual and pooled csDMARD combinations for each trial. A meta-analysis was also performed on pooled data for HAQ-DI and DAS28 (CRP) across interventional trials.
Results: Across all four studies, 731 patients received abatacept plus one non-MTX csDMARD (hydroxychloroquine n = 152; sulfasalazine n = 123; azathioprine n = 59; and leflunomide n = 397) and 2382 patients received abatacept plus MTX. Mean changes from baseline in HAQ-DI scores for abatacept plus MTX (all csDMARDs pooled) vs abatacept plus a non-MTX csDMARD were –0.54 vs –0.44 (ATTAIN), –0.43 vs –0.43 (ASSURE), and –0.39 vs –0.36 (ARRIVE). Mean changes from baseline in DAS28 (CRP) and ACR response rates were also similar with abatacept plus MTX or non-MTX csDMARDs. Data for individual non-MTX csDMARDs (pooled across studies) and real-world data were consistent with these findings. Rates of treatment-related adverse events and serious adverse events, respectively, for abatacept plus one non-MTX csDMARD vs abatacept plus MTX were 35.7% vs 41.7% and 2.4% vs 2.3% (ATTAIN), 58.0% vs 55.9% and 4.2% vs 1.7% (ASSURE), and 38.1% vs 44.3% and 0.6% vs 2.9% (ARRIVE).
Conclusions: Abatacept in combination with non-MTX csDMARDs is clinically effective and well tolerated in patients with moderate-to-severe RA, providing similar benefits to those seen with abatacept plus MTX.
Background: We analyzed whether co-occurring mutations influence the outcome of systemic therapy in ALK-rearranged non-small-cell lung cancer (NSCLC).
Patients and methods: ALK-rearranged stage IIIB/IV NSCLC patients were analyzed with next-generation sequencing and fluorescence in situ hybridization analyses on a centralized diagnostic platform. Median progression-free survival (PFS) and overall survival (OS) were determined in the total cohort and in treatment-related sub-cohorts. Cox regression analyses were carried out to exclude confounders.
Results: Among 216 patients with ALK-rearranged NSCLC, the frequency of pathogenic TP53 mutations was 23.8%, while other co-occurring mutations were rare events. In ALK/TP53 co-mutated patients, median PFS and OS were significantly lower compared with TP53 wildtype patients [PFS 3.9 months (95% CI: 2.4–5.6) versus 10.3 months (95% CI: 8.6–12.0), P < 0.001; OS 15.0 months (95% CI: 5.0–24.9) versus 50.0 months (95% CI: 22.9–77.1), P = 0.002]. This difference was confirmed in all treatment-related subgroups including chemotherapy only [PFS first-line chemotherapy 2.6 months (95% CI: 1.3–4.1) versus 6.2 months (95% CI: 1.8–10.5), P = 0.021; OS 2.0 months (95% CI: 0.0–4.6) versus 9.0 months (95% CI: 6.1–11.9), P = 0.035], crizotinib plus chemotherapy [PFS crizotinib 5.0 months (95% CI: 2.9–7.2) versus 14.0 months (95% CI: 8.0–20.1), P < 0.001; OS 17.0 months (95% CI: 6.7–27.3) versus not reached, P = 0.049] and crizotinib followed by next-generation ALK-inhibitor [PFS next-generation inhibitor 5.4 months (95% CI: 0.1–10.7) versus 9.9 months (95% CI: 6.4–13.5), P = 0.039; OS 7.0 months versus 50.0 months (95% CI: not reached), P = 0.001).
Conclusions: In ALK-rearranged NSCLC co-occurring TP53 mutations predict an unfavorable outcome of systemic therapy. Our observations encourage future research to understand the underlying molecular mechanisms and to improve treatment outcome of the ALK/TP53 co-mutated subgroup.
Es gehört zu den Grundüberzeugungen der aktuellen Kulturanthropologie, dass der moderne Mensch in seiner mentalen Konstitution unter anderem das Ergebnis jener 'drei Kränkungen' sei, die er auf seinem Weg in die gegenwärtige Moderne erfahren habe und die Sigmund Freud in der Krisenerfahrung der europäischen Zivilisation während des 1. Weltkrieges formuliert hatte. Zu diesen drei Kränkungen gehört auch die sogenannte 'kosmologische Beleidigung'. Diese steht geradezu emblematisch an jenem Anfang der aktuellen Moderne, als im Zuge zunehmender Entdeckungen sowohl in geographischer als auch in kosmologischer Hinsicht der europäische Mensch die Vorstellung von der herausragenden Bedeutung seiner Stellung in Gottes Schöpfung - oder etwas säkularisierter: in diesem Universum - verabschieden musste. Er durfte einsehen, dass diese Welt nicht für ihn von dem geschaffen wurde, den er sich als seinen Gott vorstellte, sondern dass er ein zufälliges Nebenprodukt eines viel umfangreicheren evolutionären Prozesses war. Aus dieser Einsicht resultiert die Vorstellung von der Kleinheit und Bedeutungslosigkeit des Menschen, die schließlich angesichts der erkannten Unendlichkeit des Universums zu der Erfindung der Denkformel führt, dass der Mensch im Universum einsam sei und dieser Umstand ihn erschüttere. Im Nachfolgenden soll es darum gehen, die Entwicklung dieser Formel zu verfolgen. Dabei fällt sofort auf und erfordert theoretische Reflexionen, dass dieser Mythos immer wieder in den verschiedensten Medien, Diskurstypen und Kunstformen auftaucht: vom philosophisch-moralistischen Staatstraktat wie Ciceros "De re publica" aus dem 1. Jh. v. u. Z. bis zu David Bowies Top 20-Hit wie "Space Oddity" aus dem Jahre 1969 über Major Tom und darüber hinaus, - ein Problem, welches man nur mit einer erweiterten Theorie der Intertextualität und der Intermedialität angemessen erfassen kann.
Background: While recent data show that crizotinib is highly effective in patients with ROS1 rearrangement, few data is available about the prognostic impact, the predictive value for different treatments, and the genetic heterogeneity of ROS1- positive patients.
Patients and methods: 1137 patients with adenocarcinoma of the lung were analyzed regarding their ROS1 status. In positive cases, next-generation sequencing (NGS) was performed. Clinical characteristics, treatments and outcome of these patients were assessed. Overall survival (OS) was compared with genetically defined subgroups of ROS1-negative patients.
Results: 19 patients of 1035 evaluable (1.8%) had ROS1-rearrangement. The median OS has not been reached. Stage IV patients with ROS1-rearrangement had the best OS of all subgroups (36.7 months, p < 0.001). 9 of 14 (64.2%) patients had at least one response to chemotherapy. Estimated mean OS for patients receiving chemotherapy and crizotinib was 5.3 years. Ten patients with ROS1-rearrangement (52.6%) harbored additional aberrations.
Conclusion: ROS1-rearangement is not only a predictive marker for response to crizotinib, but also seems to be the one of the best prognostic molecular markers in NSCLC reported so far. In stage IV patients, response to chemotherapy was remarkable high and overall survival was significantly better compared to other subgroups including EGFR-mutated and ALK-fusion-positive NSCLC.